Dr. Jorge Nieva is Associate Professor of Clinical Medicine at the Keck School of Medicine of the University of Southern California. He is a member of the USC/Norris Comprehensive Cancer Center and Section Head of Thoracic and Head/Neck Tumors. Dr. Nieva is an internationally

Stronger MRI magnets are not always better. Using a low strength magnet with faster image acquisition times, we can screen for lung cancer using MRI without radiation exposure. onlinelibrary.wiley.com/doi/10.1002/mr…

Dr. Jorge Nieva now presenting #KRAS and #BRAF. What is signaling? Why do mutations in KRAS and BRAF mess it up? #TargetedTherapiesInLungCancer #LungCancer

My friend Jorge Nieva from USC Norris Comprehensive Cancer Center is speaking on KRAS & BRAF as part of GRACE Targeted Therapies Forum, explaining complex science in a remarkably accessible way. Beautiful job in a tough task!

#Smoking is associated with #KRAS (~100%) and #BRAF (50%) alterations. • Increases cancers of upper airway, stomach, mouth, tongue, liver, cervix, bladder… • So: Don’t start smoking • If you smoke, quit. Your risk of cancer starts coming down about two years. • Quitting is

We are publishing EGFR resistant tumor data here after profiling more than 45,000 tumors, the documentation of the prevalence of resistance mutations (718,721,797 etc.) is very important however we need to increase awareness to repeat molecular profiling after TKI failure to have

A great conference for all who are interested in lung cancer. gotoper.com/courses/intern…

On July 17th, come to Pasadena to hear about lung cancer updates at our OncLive State of the Science Summit! registration.onclive.com/state-of-the-s…

healio.com/news/hematolog…

healio.com/news/hematolog…

Tune in tomorrow for the latest episode of the IASLC podcast, Lung Cancer Considered, where I discuss the recent FDA approval of taletrectinib in #ROS1 NSCLC, with Drs. Jorge Nieva and Enriqueta Felip. Where will this drug fit into the treatment landscape? Download tomorrow!

The FDA has approved taletrectinib for ROS1+ NSCLC, but what does that mean for clinical practice? On #LungCancerConsidered, Stephen V Liu, MD, Enriqueta Felip & Jorge Nieva discuss this approval & how to position taletrectinib among treatment options. 🎧 bit.ly/FDATaletrectin…

Join OncLive LIVE July 23, 3:30 PM PT. Engage w/ Narjust Florez, MD, Edward S. Kim, MD, Eric K. Singhi, MD & vote in interactive polls! See how your answers align w/ experts. Follow OncLive.com & click 🔔 for alerts! #BTGLung2025 Eric K. Singhi, MD Edward S. Kim, MD, MBA, FACP, FASCO Narjust Florez, MD, FASCO

‼️Polling Q2. Emerging treatment options in SCLC What do you see as the most promising strategy to improve OS in SCLC? #BTGLung2025 Jacob sands Triparna Sen (Sen-Lab) Narjust Florez, MD, FASCO Edward S. Kim, MD, MBA, FACP, FASCO Ana I. Velázquez Mañana, MD, MSc, FASCO OncLive.com

Diving beyond EGFR in NSCLC with an excellent session chaired by Erin Schenk, MD, PhD, featuring a stellar lineup of talks on KRAS, BRAF, ROS1, MET, RET, and more! With insights from Christine Garcia, MD, MPH David Gandara Mihaela Aldea Jorge Nieva Jonathan Riess, MD MS OncLive.com #BTGLung2025 #LCSM #Oncology

A huge thanks to Jorge Nieva, of Keck School of Medicine of USC, who stopped by during #BTGLung2025 to talk about the management of ALK rearrangements in NSCLC! Check out our site for exclusive insights from Dr Nieva and more! #lcsm #oncology onclive.com/bridging-the-g…

Greetings from Huntington Beach, CA.

lungcancerstoday.com/post/bedside-t…

💊 How do steroids impact survival in patients undergoing immunotherapy for NSCLC? 🫁 Don't miss this insightful interview with Jorge Nieva of Keck Medicine of USC, who discusses recent bedside-to-bench research that addressed the question. ➡️ Watch: buff.ly/FI2FBsS #lcsm

Very proud of Rahul Mudumba for completing this important pharmaco-economic analysis of ALK fusion lung cancer treatment. jmcp.org/doi/full/10.18…